-
Mashup Score: 1COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint - 1 year(s) ago
In an effort to contain the COVID-19 pandemic, multiple vaccines based on different platforms were rapidly developed and used worldwide. As of April 7, 2023, over 13·3 billion vaccine doses have been administered globally. Although vaccines prevented symptomatic infections with SARS-CoV-2, these vaccines did not offer sterile immunity. In The Lancet Respiratory Medicine, Nana Wu and colleagues1…
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 3
Sleep disturbance following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness. Due to the association with multiple symptoms, targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition.
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
The CanPredict (lung) model was developed, and internally and externally validated, using data from 19·67 million people from two English primary care databases. Our model has potential utility for risk stratification of the UK primary care population and selection of individuals at high risk of lung cancer for targeted screening. If our model is recommended to be implemented in primary care,…
Source: The Lancet Respiratory MedicineCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0
We read with great interest the EuroECMO-COVID study1 in The Lancet Respiratory Medicine. Roberto Lorusso and colleagues should be congratulated for this important research, which contributes to our understanding of the long-term outcomes of COVID-19 in the most severe forms of disease treated with extracorporeal membrane oxygenation (ECMO). However, we would like to draw attention to missing…
Source: The Lancet Respiratory MedicineCategories: Critical Care, Latest HeadlinesTweet
-
Mashup Score: 0Small lung syndrome: the need to reclassify chronic lung disease - 1 year(s) ago
In 1958, an international symposium defined a category of “non-specific lung disease”, which excluded all neoplasms, infections, and diseases caused by other known (mostly occupational) exposures.1 This grouping included bronchitis (defined by symptoms), emphysema (defined by histology), and airflow obstruction, both reversible (asthma) and irreversible (later called chronic obstructive pulmonary…
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0NUTRIREA-3: where to next? - 1 year(s) ago
Observational data dating back more than three decades showing an association between malnutrition and poor outcomes in patients with critical illness has led to an extrapolation that full calorie and protein provision in the form of artificial nutrition would improve outcomes in critically ill patients. This association has not been supported by recent randomised trials; instead evidence…
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random? - 1 year(s) ago
Ethnicity-related differences in the prevalence, age at presentation, and mortality of interstitial lung disease remain inadequately understood. The scarcity of such information is especially notable with respect to non-White individuals including those of so-called Asian ethnicity. The imprecise and generic grouping of different ethnicities under this term is embedded in the medical literature…
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Small lung syndrome: the need to reclassify chronic lung disease - 1 year(s) ago
In 1958, an international symposium defined a category of “non-specific lung disease”, which excluded all neoplasms, infections, and diseases caused by other known (mostly occupational) exposures.1 This grouping included bronchitis (defined by symptoms), emphysema (defined by histology), and airflow obstruction, both reversible (asthma) and irreversible (later called chronic obstructive pulmonary…
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study - 1 year(s) ago
To our knowledge, this is the first study to characterise lifetime phenotypes of obstruction and restriction simultaneously using objective data-driven techniques and unique life course spirometry measures of FEV1/FVC ratio and FVC from childhood to middle age. Mixed and obstructive-only patterns indicate those who might benefit from early COPD interventions. Those with the restrictive-only…
Source: The Lancet Respiratory MedicineCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Long COVID? What is that? - 1 year(s) ago
Some people do not believe long COVID (also known as post-COVID-19 condition) is real. In fact, patients have reported that there are even doctors who sit in this camp, who might dismiss their symptoms as psychosomatic, or do not know how to recognise or treat long COVID. It is complicated, even for researchers. People might not have had severe symptoms when infected with SARS-CoV-2 virus, they…
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
NEW Linked Comment—#COVID19 vaccine effectiveness and evolving variants: understanding the immunological footprint From Luca M Zaeck & colleagues https://t.co/LFqmvjWgQJ Linked to Article https://t.co/uswcJMJlBC https://t.co/wZI5HUqZBj